This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Stock Moves -1.06%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $124.71, marking a -1.06% move from the previous day.
Abbott (ABT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott's (ABT) Organic Base Sales Grow Amid COVID Case Surge
by Zacks Equity Research
Even though COVID-19 case rates are surging, Abbott (ABT) is registering growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
Abbott (ABT) Gets FDA Nod for New Cardiac Mapping System
by Zacks Equity Research
Abbott's (ABT) EnSite X EP System with EnSite Omnipolar Technology offers a 360-degree view of the heart, regardless of catheter orientation, for cardiac mapping without compromise.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $135.70, marking a +0.33% move from the previous day.
Why Abbott (ABT) Could Beat Earnings Estimates Again
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AngioDynamics (ANGO) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs, as well as in domestic and international revenues in fiscal 2022 Q2.
Illumina (ILMN)-SomaLogic Ink Deal to Advance Proteomics
by Zacks Equity Research
Illumina's (ILMN) collaboration with SomaLogic will boost the fast-growing high throughput sector of the proteomics market to aid research in biology and disease.
Abbott's (ABT) Proclaim XR SCS Gets FDA Nod for New MRI Label
by Zacks Equity Research
The latest FDA approval is set to augment Abbott's (ABT) Neuromodulation arm, which is having a hard time amid the COVID spell due to its elective nature of business.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $139.04, marking a -1.21% move from the previous day.
Abbott (ABT) Stock Moves -0.18%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $140.74, marking a -0.18% move from the previous day.
Here's Why You Should Invest in Abbott (ABT) Stock Right Now
by Zacks Equity Research
Riding on current business growth and bullish near-term prospects, Abbott (ABT) is worth investing in for now.
The Zacks Analyst Blog Highlights: Apple, Abbott Laboratories, Infosys, General Motors and NIO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Abbott Laboratories, Infosys, General Motors and NIO
Top Stock Reports for Apple, Abbott & Infosys
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Abbott Laboratories (ABT), and Infosys Limited (INFY).
Abbott (ABT) Diagnostic and Nutrition Arms Grow Worldwide
by Zacks Equity Research
Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $140.47 in the latest trading session, marking a -0.7% move from the prior day.
AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
Abbott (ABT) Scales to a 52-Week High: What's Driving It?
by Zacks Equity Research
Strength in Diabetes Care and Diagnostics businesses is driving Abbott's (ABT) top line.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $135.27 in the latest trading session, marking a +0.21% move from the prior day.
3 Reasons Why Abbott (ABT) Is a Great Growth Stock
by Zacks Equity Research
Abbott (ABT) possesses solid growth attributes, which could help it handily outperform the market.
ABT or RMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ABT vs. RMD: Which Stock Is the Better Value Option?
Is Abbott (ABT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Abbott (ABT) and Organogenesis (ORGO) have performed compared to their sector so far this year.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $135.56, moving +1.97% from the previous trading session.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $132.37 in the latest trading session, marking a -0.04% move from the prior day.